tetano
Editor, Senior Moderator
Endocrine
. 2020 Aug 10.
doi: 10.1007/s12020-020-02444-9. Online ahead of print.
Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review
Giuseppe Lisco[SUP] 1 [/SUP], Anna De Tullio[SUP] 2 [/SUP], Vito Angelo Giagulli[SUP] 2 3 [/SUP], Edoardo Guastamacchia[SUP] 2 [/SUP], Giovanni De Pergola[SUP] 4 [/SUP], Vincenzo Triggiani[SUP] 2 [/SUP]
Affiliations
Abstract
Purpose: Epidemiological data suggest that comorbid patients, mostly those with type 2 diabetes (T2D), are predisposed to poor prognosis in Coronavirus disease 2019 (COVID-19), leading to serious healthcare concerns. The aim of the present manuscript is to review the main relevant mechanisms possibly contributing to worsen the clinical course of COVID-19 in T2D.
Results: Poor glucose control, high glycaemic variability and diabetes-related comorbidities at baseline, particularly cardiovascular diseases and obesity, contribute in worsening the prognosis in the above-mentioned cluster of patients. Moreover, both a lower efficient innate immune system response and cytokine dysregulation predispose patients with T2D to impaired viral clearance and more serious pulmonary and systemic inflammation once the SARS-CoV-2 infection occurred. Inconclusive data are currently available for specifically indicate or contraindicate concurrent medications for managing T2D and its comorbidities in infected patients.
Conclusions: T2D individuals should be considered as more vulnerable to COVID-19 than general population, and thus require adequate advices about hygienic tips to protect themselves during the pandemic. A careful management of glucose levels and diabetes-related comorbidities remains essential for avoiding further complications, and patient monitoring during the pandemic should be performed also at distance by means of telemedicine. Further studies are needed to clarify whether medications normally used for managing T2D and its associated comorbidities could have a protective or detrimental effect on COVID-19 clinical course.
Keywords: COVID-19; Cardiovascular disease; Diabetes mellitus; GLP-1RAs; Immune response; Obesity.
. 2020 Aug 10.
doi: 10.1007/s12020-020-02444-9. Online ahead of print.
Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review
Giuseppe Lisco[SUP] 1 [/SUP], Anna De Tullio[SUP] 2 [/SUP], Vito Angelo Giagulli[SUP] 2 3 [/SUP], Edoardo Guastamacchia[SUP] 2 [/SUP], Giovanni De Pergola[SUP] 4 [/SUP], Vincenzo Triggiani[SUP] 2 [/SUP]
Affiliations
- PMID: 32779091
- DOI: 10.1007/s12020-020-02444-9
Abstract
Purpose: Epidemiological data suggest that comorbid patients, mostly those with type 2 diabetes (T2D), are predisposed to poor prognosis in Coronavirus disease 2019 (COVID-19), leading to serious healthcare concerns. The aim of the present manuscript is to review the main relevant mechanisms possibly contributing to worsen the clinical course of COVID-19 in T2D.
Results: Poor glucose control, high glycaemic variability and diabetes-related comorbidities at baseline, particularly cardiovascular diseases and obesity, contribute in worsening the prognosis in the above-mentioned cluster of patients. Moreover, both a lower efficient innate immune system response and cytokine dysregulation predispose patients with T2D to impaired viral clearance and more serious pulmonary and systemic inflammation once the SARS-CoV-2 infection occurred. Inconclusive data are currently available for specifically indicate or contraindicate concurrent medications for managing T2D and its comorbidities in infected patients.
Conclusions: T2D individuals should be considered as more vulnerable to COVID-19 than general population, and thus require adequate advices about hygienic tips to protect themselves during the pandemic. A careful management of glucose levels and diabetes-related comorbidities remains essential for avoiding further complications, and patient monitoring during the pandemic should be performed also at distance by means of telemedicine. Further studies are needed to clarify whether medications normally used for managing T2D and its associated comorbidities could have a protective or detrimental effect on COVID-19 clinical course.
Keywords: COVID-19; Cardiovascular disease; Diabetes mellitus; GLP-1RAs; Immune response; Obesity.